{"disease":{"id":"pancreatic","name":"pancreatic"},"drugs":{"marketed":[{"drug_id":"everolimus","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"octreotide","indication_name":"Diarrhea from Pancreatic VIPoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandostatin","generic_name":"OCTREOTIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"Somatostatin Analog","quality_score":75,"revenue":"305","mechanism":"Sandostatin works by mimicking the natural hormone somatostatin to inhibit the release of various hormones and growth factors."},{"drug_id":"pancrelipase","indication_name":"Exocrine Pancreatic Insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PANCRELIPASE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":36,"revenue":null,"mechanism":"Pancreatic enzyme products catalyze the breakdown of fats, proteins, and starches in the duodenum and proximal small intestine, mimicking natural pancreatic enzymes."},{"drug_id":"pancrelipase","indication_name":"Exocrine Pancreatic Insufficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PANCRELIPASE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":36,"revenue":null,"mechanism":"Pancreatic enzyme products catalyze the breakdown of fats, proteins, and starches in the duodenum and proximal small intestine, mimicking natural pancreatic enzymes."},{"drug_id":"gymnema-sylvestre","indication_name":"Pancreatic support","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gymnema Sylvestre","company_name":"University of Guadalajara","drug_phase":"marketed","molecular_target":"","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic pancreatic cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"streptozocin","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zanosar","generic_name":"STREPTOZOCIN","company_name":"Teva","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sunitinib","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"sunitinib-malate","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunitinib Malate","generic_name":"sunitinib-malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":80,"revenue":null,"mechanism":"Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET."},{"drug_id":"afinitor","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."},{"drug_id":"sutent","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"Sunitinib Malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET","drug_class":"Small molecule kinase inhibitor","quality_score":67,"revenue":null,"mechanism":"Sunitinib inhibits multiple receptor tyrosine kinases implicated in tumor growth, angiogenesis, and metastatic progression."},{"drug_id":"pancreozymin","indication_name":"Pancreatic function test","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pankreozymin","generic_name":"pancreozymin","company_name":"","drug_phase":"unknown","molecular_target":"Cholecystokinin receptor type A","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Pankreozymin works by binding to the cholecystokinin receptor type A, mimicking the natural hormone cholecystokinin."},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of pancreatic cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"tolbutamide","indication_name":"Diagnostic Test for Pancreatic Islet Cell Adenoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aglicid","generic_name":"TOLBUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"streptozotocin","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Streptozotocin","company_name":"Hoffmann-La Roche","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"capecitabine","indication_name":"Adjuvant treatment of pancreatic adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"cholecystokinin","indication_name":"Pancreatic function test","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cholecystokinin","company_name":"University Hospital, Gentofte, Copenhagen","drug_phase":"phase_1","molecular_target":"Cholecystokinin receptor type A, Gastrin/cholecystokinin type B receptor, Cholecystokinin receptor type A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"sunitinib","indication_name":"Pancreatic Neuroendocrine Tumors (pNET)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."}],"pipeline":[],"offLabel":[],"totalMarketed":19,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06632886","title":"AI-Assisted Non-Contrast CT for Multi-Cancer Screening","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Guo ShiWei","has_results":false},{"nct_id":"NCT07177599","title":"Pancreatic Disease Burden in Older Adults (1990-2040)","phase":"","overall_status":"COMPLETED","enrollment_count":723415,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT04334239","title":"Effectiveness of Care in Certified Cancer Centres in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":670000,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT07117045","title":"Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":400000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06528223","title":"Research of the Application of Artificial Intelligence Model \"PANDA\"","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06643715","title":"Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model \"PANDAPro\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06389890","title":"Pancreatic Surgery - Optimal Caseload Thresholds and Predictive Accuracy","phase":"","overall_status":"COMPLETED","enrollment_count":80000,"lead_sponsor_name":"Richard Hunger","has_results":false},{"nct_id":"NCT07446946","title":"Surgical Management of Pancreatic Cancer With Liver Metastasis (Oligometastasis)","phase":"","overall_status":"COMPLETED","enrollment_count":68303,"lead_sponsor_name":"Richard Hunger","has_results":false},{"nct_id":"NCT05253859","title":"CFTR Modulators and Gastrointestinal Complications","phase":"","overall_status":"COMPLETED","enrollment_count":47023,"lead_sponsor_name":"Nottingham University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT06106568","title":"An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":39624,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT06271291","title":"Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05663515","title":"A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","phase":"","overall_status":"RECRUITING","enrollment_count":24000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06995898","title":"The Vanguard Study: Testing a New Way to Screen for Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":24000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04970056","title":"Pancreatic Cancer Early Detection Consortium","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Arbor Research Collaborative for Health","has_results":false},{"nct_id":"NCT05141656","title":"Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT00830557","title":"Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04984174","title":"Survival Rate and Treatment Cost in Patients With Pancreatic Cancer: An Analysis Using NHIS Database and K-PaC Registry Focusing on Liposomal Irinotecan","phase":"","overall_status":"COMPLETED","enrollment_count":14760,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT03791450","title":"Investigation of Pancreaticoduodenectomy","phase":"","overall_status":"COMPLETED","enrollment_count":10085,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03517332","title":"Circulating Tumor DNA Exposure in Peripheral Blood","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Quantgene Inc.","has_results":false},{"nct_id":"NCT05431517","title":"Incidence, Risk Factors and Endoscopic Retrieval of Proximally Migrated Pancreatic Stents","phase":"","overall_status":"COMPLETED","enrollment_count":9073,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT04075305","title":"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT04237441","title":"The Results of Pancreatic Operations After the Implementation of Multidisciplinary Team Conference (MDT):","phase":"","overall_status":"COMPLETED","enrollment_count":7294,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT07171515","title":"Development & Clinical Application of K-PaC Registry Version 2.0","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":6923,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT07022639","title":"Influence of Hospital Volume on Mortality and Length of Hospital Stay After Pancreatic Resection in Switzerland","phase":"","overall_status":"COMPLETED","enrollment_count":6785,"lead_sponsor_name":"Cantonal Hospital of St. Gallen","has_results":false},{"nct_id":"NCT05479292","title":"Allocating Resources for Cancer Care in Times of the Sars-CoV-2 Outbreak. Health Care Research","phase":"","overall_status":"COMPLETED","enrollment_count":6500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT07243262","title":"Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)","phase":"","overall_status":"RECRUITING","enrollment_count":6079,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT06717295","title":"The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Javier Toledo","has_results":false},{"nct_id":"NCT04259580","title":"Calgary Registry for Advanced and Therapeutic Endoscopy","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT06440018","title":"INSPIRE: a Multi-Cancer Early Detection Study","phase":"","overall_status":"RECRUITING","enrollment_count":5350,"lead_sponsor_name":"Singlera Genomics Inc.","has_results":false},{"nct_id":"NCT06344299","title":"Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":5302,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03662204","title":"Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":5133,"lead_sponsor_name":"Exact Sciences Corporation","has_results":false},{"nct_id":"NCT04802993","title":"Survival Among Patients With Pancreatic Cancer Depending on Surgical Resection Rate","phase":"","overall_status":"COMPLETED","enrollment_count":5123,"lead_sponsor_name":"Linkoeping University","has_results":false},{"nct_id":"NCT06151223","title":"A Prospective Registry for Patients at High-Risk for Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04473794","title":"Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04743479","title":"Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06122896","title":"Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT05051358","title":"Therapeutic Endoscopic Ultrasound for Gastrointestinal Disorders: A Multicenter Registry Study","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Advanced Endoscopy Research, Robert Wood Johnson Medical School Rutgers University","has_results":false},{"nct_id":"NCT06055010","title":"Improving Pancreatic Cancer Care by the Use of Computational Science and Technology","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT05463796","title":"InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT04949282","title":"Spanish Series of Patients Treated With the Radionuclide Lutetium177","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Sociedad Española de Medicina Nuclear e Imagen Molecular","has_results":false},{"nct_id":"NCT06638866","title":"AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT03311776","title":"BIOmarkers in Patients With Pancreatic Cancer (\"BIOPAC\")","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Inna Chen, MD","has_results":false},{"nct_id":"NCT04239573","title":"Comparing Two Methods to Follow Patients With Pancreatic Cysts","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4606,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT03172572","title":"A Pan-European Study on Minimally Invasive Versus Open Pancreatoduodenectomy in High-volume Centers","phase":"","overall_status":"COMPLETED","enrollment_count":4220,"lead_sponsor_name":"S (Sjors) Klompmaker, MD","has_results":false},{"nct_id":"NCT05776342","title":"Prognostic and Predictive Markers of Treatment Response in Patients With PAC.","phase":"","overall_status":"RECRUITING","enrollment_count":4050,"lead_sponsor_name":"GERCOR - Multidisciplinary Oncology Cooperative Group","has_results":false},{"nct_id":"NCT03513705","title":"Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)","phase":"NA","overall_status":"COMPLETED","enrollment_count":4000,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT04291651","title":"UCSF PANC Cyst Registry","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"University of California, San Francisco","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}